Greenwich LifeSciences
GLSIGreenwich LifeSciences is a clinical-stage biopharmaceutical company focused on developing immunotherapies to prevent breast cancer recurrences.
Table of contents
Earnings
Next report
Aug 13, 2026 (in a month)Competitors
By market cap
By revenue growth
Profile
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on developing immunotherapies to prevent breast cancer recurrences. Its primary asset is GLSI-100, a combination of the GP2 peptide and a GM-CSF adjuvant, currently being evaluated in the Phase III Flamingo-01 clinical trial. The company targets patients with HER2/neu positive breast cancer who have completed standard-of-care surgical and adjuvant treatments.
A clinical-stage developer with a Phase III candidate targeting a specific niche in the HER2/neu breast cancer market, competing against established pharmaceutical giants and emerging biotech firms.
Questions, answered.
- What is Greenwich LifeSciences's market cap?
- Greenwich LifeSciences (GLSI) has a market capitalization of $287.3M and trades on NASDAQ.
- Who are Greenwich LifeSciences's competitors?
- Greenwich LifeSciences's key competitors include Puma Biotechnology, AstraZeneca PLC, Merck & Co., and others. These companies compete in similar markets and product categories.
- Who does Greenwich LifeSciences partner with?
- Greenwich LifeSciences's notable partners include Henry M. Jackson Foundation, Baylor College of Medicine, MD Anderson Cancer Center.
- Where is Greenwich LifeSciences headquartered?
- Greenwich LifeSciences is headquartered in United States of America and employs approximately 6 people. It has been publicly traded since 2020.